VIKING GLOBAL INVESTORS LP
SEC insider (Form 3/4/5 filer). CIK 0001103804. 10% Owner at Inhibrx Biosciences, Inc. (INBX) and 2 other issuers. 5 reported Form 4/5 transactions since Sep 2024; latest on Oct 7, 2025. Located in STAMFORD, CT.
Companies VIKING GLOBAL INVESTORS LP has filed insider reports for
- Inhibrx Biosciences, Inc. (INBX): 10% Owner
- BridgeBio Pharma, Inc. (BBIO): 10% Owner
- ACUREN CORP (TIC): 10% Owner
VIKING GLOBAL INVESTORS LP
CIK: 0001103804
Transaction Breakdown
Open Market Buys (P)0 (0.0%)
High conviction signal
Open Market Sales (S)5 (100.0%)
Position reduction
Option Exercises (M)0 (0.0%)
Derivative conversions
Awards (A)0 (0.0%)
Compensation grants
Other (G, F, J, C, D, …)0 (0.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (5 total)
- Oct 7, 2025INBX
Inhibrx Biosciences, Inc.
SaleIndirect308.6K shares at avg. $32.25$10.0M - Oct 7, 2025INBX
Inhibrx Biosciences, Inc.
SaleIndirect16.3K shares at avg. $32.25$526K - Oct 7, 2025INBX
Inhibrx Biosciences, Inc.
SaleIndirect25K shares at avg. $32.25$808K - Jun 27, 2025BBIO
BridgeBio Pharma, Inc.
SaleIndirect3.5M shares at avg. $44.00$154.0M - Jan 31, 2025BBIO
BridgeBio Pharma, Inc.
SaleIndirect3.1M shares at avg. $34.90$107.0M
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Oct 7, 2025 |  INBX Inhibrx Biosciences, Inc. | Sale | 308,643 | $32.25 | $9,953,737 | Indirect |
| Oct 7, 2025 | INBX Inhibrx Biosciences, Inc. | Sale | 16,315 | $32.25 | $526,159 | Indirect |
| Oct 7, 2025 | INBX Inhibrx Biosciences, Inc. | Sale | 25,042 | $32.25 | $807,605 | Indirect |
| Jun 27, 2025 |  BBIO BridgeBio Pharma, Inc. | Sale | 3,500,000 | $44.00 | $154,000,000 | Indirect |
| Jan 31, 2025 | BBIO BridgeBio Pharma, Inc. | Sale | 3,065,616 | $34.90 | $106,989,998 | Indirect |
1-5 of 5 transactions